Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma.
Mantle-cell lymphoma (MCL) is a B-cell tumour with a usually poor prognosis, characterized by the proliferation of small cleaved lymphocytes with a diffuse growth pattern. We report a polymerase chain reaction-based analysis of minimal residual disease in a patient who achieved complete remission after allogeneic blood cell transplantation (BCT). Rearrangement of the immunoglobulin heavy-chain genes was used to generate a lymphoma-specific molecular marker. Lymphoma cells were not detectable in a bone marrow sample collected 12 months after BCT. Our findings suggest that allogeneic BCT may offer a curative approach to MCL.
Corradini
P
P
Department of Medicine and Experimental Oncology, University of Torino, Italy.
Ladetto
M
M
Astolfi
M
M
Voena
C
C
Tarella
C
C
Bacigalupo
A
A
Pileri
A
A
D000328:Adult; D016913:Blood Component Transfusion / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D018365:Neoplasm, Residual; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D012074:Remission Induction; D014184:Transplantation, Homologous